**Supporting Table 1: Primers for PCR amplification of the POLE exonuclease domain**

|  |  |  |  |
| --- | --- | --- | --- |
| **Exon** | **Forward** | **Reverse** | **Size (bp)** |
| 9 | GGGTCCTTCTCCCAGCTCTA | GTACAGCTGGAGGTCGGAAC | 400 |
| 10 | CCGTCTCTGGCAGAAAAGAC | CCACACACAGAGCGTCTCTT | 423 |
| 11 | GGGCAGGTCAGGCTCTAATG | AACATGAGGCTGCTGCTTCT | 369 |
| 12 | GCTGCCATACTCTTGGGTGA | ATTTGAGAGGGAGGGCGTTG | 445 |
| 13 | CTACACCATGTGGGGCCTTG | CAGTAAGGAGACCGGCACAG | 474 |
| 14 | CACACCAGGGCCAGAGAATT | CGGGACACACGTGTTTTGTC | 431 |
| 60°C annealing temperature. | | | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supporting Table 2: Stepdown final multivariable analysis of progression-free and overall survival in endometrioid EC** | | | | | | | | | |  |
| **Variable** | **Progression-free survival** | | | | **Overall Survival** | | | |
| Hazard ratio (95% CI) | Std. Error | z | *p* value | Hazard ratio (95% CI) | Std. Error | z | *p* value |
|
| Advanced age (>60 y) | - | - | - | - | 2.36 (1.66-3.36) | .426 | 4.76 | **<.001** |
| Advanced stage (I/II vs III/IV) | 3.18 (1.90-5.32) | .835 | 4.4 | **<.001** | 2.74 (1.90-3.96) | .514 | 5.38 | **<.001** |
| High grade (1 vs 2/3) | 2.85 (1.57-5.15) | .862 | 3.45 | **.001** | 1.65 (1.19-2.28) | .273 | 3.03 | **.002** |
| Presence of LVSI | 2.10 (1.23-3.60) | .577 | 2.71 | **.007** | 1.76 (1.27-2.44) | .293 | 3.38 | **.001** |
| All variables with a *p* value less than 0.1 in univariate analysis were included in the multivariable model. | | | | | | | | |